Post-Vaccination Biological Collection
NCT03875703 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200
Last updated 2020-12-14
Summary
Introduction: Vaccination is a powerful weapon in the fight against infectious diseases, which has led to dramatic reduction in mortality and complications from some diseases. In this respect, vaccination is a real worldwide public health challenge (WHO). Thus, vaccine research benefits from an exponential development of knowledge in immunology and biotechnology. In particular, the advent of recent tools ("omics", new cytometric assays) and the description of new categories of immune cells (Tfh, BReg...) have revolutionized the characterization of immune responses, particularly post-vaccination. To study of the immune response following vaccination remains essential in order to define the immunological correlates to vaccine protection. This response also varies according to parameters related to the vaccine (type, adjuvant, dose, regimen…) and to the vaccinated host (genetics, age, morbidity, treatment …). Analyzing with new generation immune assays, new data on immunological responses post-vaccination from a clinical cohort is therefore essential to better define these correlates.
Objective: To develop new vaccines (HIV, emerging infectious diseases) the investigators use a "System vaccinology" method to decipher the mechanisms of immune responses set up against vaccines currently being developed or marketed, specifically in specific populations (patients with primary immune deficiency, sickle cell patients, solid organ transplanted patients, COPD).
Method: Description of the genetic, molecular and cellular mechanisms of the immune response to vaccines recommended for adults, in particular influenza and pneumococcal vaccines, but also other mandatory vaccines (MMR,...) or vaccine for travelers (yellow fever, ...) as part of routine care in different population categories (healthy subjects, HIV+ subjects, COPD patients, …), using qualitative and quantitative immunological assays: transcriptional analysis of the dynamic innate immune response, analysis of the lymphocytes B \& T responses (phenotype, repertoire analysis, functional analysis including T reg and TFH populations, antibody response), genetic analysis in the context of primary immune deficiencies) Conclusion: The data generated will allow the best possible analysis of vaccine responses according to vaccines and vaccinated populations, providing important information for the research developed within the department.
Conditions
- Vaccination
- Immune Response
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
collaborator OTHER_GOV -
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Laetitia Gregoire · APHP URC
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-01
- Primary Completion
- 2030-02-01
- Completion
- 2030-02-01
Countries
- France
Study Locations
More Related Trials
-
Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies
NCT02934295 ·Status: COMPLETED ·Phase: NA
-
Antibody Response and Longevity Post SARS-CoV-2 Vaccine (SARS-AB)
NCT05515081 ·Status: COMPLETED ·Phase: NA
-
Description of the Immune Response to Yellow Fever Vaccination
NCT06718127 ·Status: RECRUITING ·Phase: NA
-
Effect of Different SARS-CoV-2 Vaccine Schedules and Vaccination Intervals on Reactogenicity and Humoral Immunogenicity
NCT05076227 ·Status: COMPLETED
-
Immune Response to Vaccination Against Covid-19, a Follow up Study
NCT04920357 ·Status: UNKNOWN
-
The Influence of Trained Immunity in COVID-19 Vaccinated Individuals
NCT05705180 ·Status: UNKNOWN
-
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
NCT04895982 ·Status: COMPLETED ·Phase: PHASE2
-
Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)
NCT06469359 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating the Duration of Immunity in Healthy Adult Volunteers Who Completed Study 6108A1-500
NCT00518492 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants
NCT03953196 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen
NCT05037266 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
NCT04816669 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults
NCT00397943 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Responses to Smallpox Vaccination
NCT00325975 ·Status: COMPLETED
-
Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines
NCT05142540 ·Status: TERMINATED
-
COVID19 Vaccination: Clinical, Laboratory and Cellular Monitoring
NCT04844632 ·Status: UNKNOWN
-
Immune Response Following COVID-19 Vaccination
NCT04736524 ·Status: UNKNOWN
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
NCT06810934 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Immunogenicity,Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine
NCT05329038 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Fourth BNT162b2 COVID-19 Vaccine Dose
NCT05231005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19
NCT04756830 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines
NCT05933512 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)
NCT05128721 ·Status: UNKNOWN ·Phase: PHASE1
-
Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)
NCT05057169 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic
NCT04435379 ·Status: COMPLETED ·Phase: PHASE3